uniQure N.V. (QURE) News Headlines

▮ More

Date

Headline

3/13/2023 7:12:18 AM UniQure Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

12/20/2022 7:47:42 AM UniQure Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

11/23/2022 10:01:41 AM UniQure Up 6% On FDA Approval Of Gene Therapy Drug

10/26/2022 6:00:44 AM Biotech Stocks Facing FDA Decision In November 2022

8/8/2022 11:48:56 AM UniQure Stock Tanks 30%

6/23/2022 10:26:45 AM UniQure Stock Jumps 15% On Study Update Of AMT-130 Gene Therapy For Huntington's Disease Treatment

5/24/2022 8:45:18 AM UniQure: FDA Accepts BLA For Etranacogene Dezaparvovec For Priority Review

5/24/2022 8:31:50 AM UniQure Says FDA Accepts BLA For Etranacogene Dezaparvovec Under Priority Review

5/3/2022 4:35:23 AM TCMD Expects 13-15% Revenue Growth In 2022, AXSM On Watch, QURE Awaits Huntington's Trial Data

3/28/2022 2:33:58 AM CSL Behring : EMA Commences Review Of Gene Therapy Candidate Etranacogene Dezaparvovec For People With Hemophilia B

3/21/2022 7:29:57 AM UniQure Completes Patient Enrollment In First Two Cohorts Of Phase I/II Trial Of AMT-130 For Huntington’s Disease

3/4/2022 7:35:15 AM Pre-market Movers: SANW, SWBI, SG, FNKO, WAVE…

12/16/2021 10:49:05 AM What Is Hurting UniQure Stock?

12/15/2021 7:35:32 AM CSL Behring Gets Accelerated CHMP Assessment For Etranacogene Dezaparvovec For Patients Living With Hemophilia B

9/7/2021 6:25:07 AM Pre-market Movers: IRNT, MTL, IFRX, FWP, JAGX, IPHA…

7/27/2021 10:00:33 AM UniQure Shares Rise On Upbeat Q2

2/9/2021 1:47:03 AM ATHE Gets Funds For Parkinson's Research, No Safety Issues For QURE's Trial, TNXP On Watch

11/22/2016 1:38:10 PM Jefferies Is Lowering uniQure N.V. (QURE) 2018 Estimate To -1.96 From -1.83

11/22/2016 1:37:47 PM Jefferies Is Cutting uniQure N.V. (QURE) 2017 Estimate To -2.23 From -2.15

11/22/2016 1:37:27 PM Jefferies Is Raising uniQure N.V. (QURE) 2016 Estimate To -2.83 From -3.40

Uniqure N.V. (QURE)